Handelsbanken Fonder AB acquired a new stake in Minerva Neurosciences, Inc (NASDAQ:NERV) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 95,000 shares of the biopharmaceutical company’s stock, valued at approximately $722,000. Handelsbanken Fonder AB owned 0.22% of Minerva Neurosciences at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Nationwide Fund Advisors lifted its stake in shares of Minerva Neurosciences by 14.2% in the 2nd quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,616 shares during the period. Citadel Advisors LLC bought a new stake in Minerva Neurosciences in the 1st quarter valued at about $110,000. Russell Investments Group Ltd. increased its position in Minerva Neurosciences by 54.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 5,579 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Minerva Neurosciences in the 2nd quarter valued at about $145,000. Finally, State of Wisconsin Investment Board bought a new stake in Minerva Neurosciences in the 2nd quarter valued at about $159,000. 69.75% of the stock is currently owned by institutional investors.
NERV has been the subject of a number of research analyst reports. Zacks Investment Research lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Citigroup Inc. started coverage on Minerva Neurosciences in a report on Friday, September 1st. They set a “buy” rating and a $11.00 price objective for the company. Finally, BidaskClub lowered Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $13.94.
Minerva Neurosciences, Inc (NASDAQ NERV) traded up $0.20 during mid-day trading on Friday, hitting $5.20. The stock had a trading volume of 494,000 shares, compared to its average volume of 218,023. Minerva Neurosciences, Inc has a 52 week low of $4.90 and a 52 week high of $14.15.
Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the company earned ($0.24) earnings per share. analysts anticipate that Minerva Neurosciences, Inc will post -1.28 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Handelsbanken Fonder AB Takes Position in Minerva Neurosciences, Inc (NASDAQ:NERV)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/11/handelsbanken-fonder-ab-takes-722000-position-in-minerva-neurosciences-inc-nerv.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.